Fort Sheridan Advisors’s Biogen BIIB Stock Holding History

Fort Sheridan Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-970	Closed	-$225K	–	250
2024 Q2	$225K	Sell	970 -100	-9%	-$21.7K	0.04%	212
2024 Q1	$231K	Buy	+1,070	New	+$251K	0.04%	182
2023 Q4	–	Sell	-995	Closed	-$256K	–	202
2023 Q3	$256K	Buy	+995	New	+$266K	0.06%	158
2022 Q4	–	Sell	-898	Closed	-$240K	–	184
2022 Q3	$240K	Buy	+898	New	+$191K	0.08%	157
2021 Q4	–	Sell	-1,100	Closed	-$311K	–	202
2021 Q3	$311K	Sell	1,100 -100	-8%	-$32.8K	0.1%	138
2021 Q2	$416K	Hold	1,200	–	–	0.14%	107
2021 Q1	$336K	Hold	1,200	–	–	0.13%	104
2020 Q4	$294K	Buy	1,200 +300	+33%	+$77.4K	0.14%	94
2020 Q3	$255K	Hold	900	–	–	0.15%	88
2020 Q2	$241K	Buy	+900	New	+$271K	0.15%	86

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fort Sheridan Advisors's BIIB Position: Q3 2024 in Review

Fort Sheridan Advisors sold out of Biogen (BIIB) in Q3 2024, closing a stake of 970 shares — an estimated $225K sold.

Fort Sheridan Advisors first reported a position in BIIB in Q2 2020 and held it in 10 quarters. The position peaked at $416K in Q2 2021. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Fort Sheridan Advisors reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Fort Sheridan Advisors sold 970 Biogen shares in Q3 2024, an estimated $225K.
Fort Sheridan Advisors first reported a position in Biogen in Q2 2020 and held it in 10 quarters.
Fort Sheridan Advisors's Biogen position peaked at $416K in Q2 2021.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Fort Sheridan Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.